Phase 2 Trial of Gene Therapy VY-AADC to Include More Parkinson’s Patients

Phase 2 Trial of Gene Therapy VY-AADC to Include More Parkinson’s Patients
The ongoing Phase 2 study of the gene therapy VY-AADC will enroll more Parkinson’s disease patients than originally planned, Voyager Therapeutics announced. The company’s revised trial protocol will include more patients — up from 75 to 100 — in the RESTORE-1 Phase 2 clinical trial (NCT03562494). Voyager also is planning to conduct a parallel Phase 3 study named RESTORE-2, with similar ... read more
Source: Parkinson’s News TodayPublished on 2019-01-09By Jose Marques Lopes, PhD